Surgery Websites
T32 Surgical Oncology »  Faculty Mentors »  Regulatory Sciences »  Kathy Giacomini, PhD
Kathy Giacomini, PhD

Kathy Giacomini, PhD

  • Professor, Bioengineering
  • Co-Director UCSF-Stanford Center of Excellence in Regulatory Sciences and Innovation

Contact Information

513 Parnassus Avenue, MSB
San Francisco, CA 94117
Phone: 415-476-8010
Fax: 415-514-4361
kathy.giacomini@ucsf.edu
Orchid: Orchid 0000-0001-8041-5430
Open Popup
The Giacomini research group focuses on expanding our understanding of membrane transporters. Membrane transporters are of great biological and pharmacological importance, as they play a major role in human physiology and in drug disposition and response. Major questions addressed in the laboratory include: What is the function of orphan membrane transporters? What is the in vivo role of membrane transporters in the disposition of endogenous solutes as well as in drug disposition and response? How does genetic variation in membrane transporters affect solute disposition, human disease and drug response? What are the structural determinants of specificity?

Dr. Kathy Giacomini is leading an effort to deorphan transporters in the Solute Carrier 22 Family, and to determine the clinical implications of specific genetic variants in membrane transporters. Research ventures, ranging from basic discovery to clinical studies, have demonstrated that common variants of membrane transporters contribute to differences in drug response in ethnically diverse populations. Ultimately, these studies will increase our knowledge of the genetic basis underlying drug response and will contribute to advancing the era of personalized medicine. Furthermore, our studies will elucidate the genetic mechanisms of decreased drug response and, ultimately, contribute to improving drug design for safe and effective treatments of subgroups of patients who do not respond to standard treatments.

Research in the laboratory focuses on drugs used in the treatment of diseases associated with metabolic syndrome. We are particularly interested in identifying the genetic determinants of the anti-diabetic drugs, metformin and sulfonylureas, highly prescribed drugs. In particular, our research focuses on discovering functional genetic variants that underlie variation in response to these drugs in large ethnically diverse patient populations. Finally, Kathy Giacomini and her collaborator, Russ Altman of Stanford University are the Co-PIs of the UCSF–Stanford Center of Excellence in Regulatory Sciences and Innovation (CERSI) funded by the Food and Drug Administration (FDA). Established in 2014 and renewed in 2021, the UCSF-Stanford CERSI aims to advance the field of regulatory sciences and improve the development and evaluation of diagnostics, therapeutics and medical devices. The UCSF-Stanford CERSI is the first FDA funded CERSI on the west coast and seeks to address key challenges related to education and research that will advance the discovery and development of medical products.

DEI Statement: As a biracial woman faculty member with ancestries in the Philippines and Europe, I am deeply committed to issues of diversity, equity and inclusion. I am a strong advocate for graduate students and postdocs of diverse ancestries and particularly under-represented minorities (URM). In my career, I have been the academic advisor for students who are URMs and who now have vibrant careers in academia and industry. My mentoring style is very personal. That is, I tailor my advising of each trainee to their career goals and aspirations, helping them to achieve these goals. On the recommendation of my students, I have institute diversity presentations as part of our regularly scheduled research group meetings. We begin each research group meeting with a diversity presentation, given by an individual group member, who describes some aspect of their cultural background. These are fun and educational and build an inclusive and welcoming environment in my laboratory. As the co-PI of the UCSF-Stanford Center of Excellence in Regulatory Sciences and Innovation, CERSI, we established a CERSI Diversity Scholars Program in 2021 and have now made four awards to the scholars (students or postdocs) at UCSF from diverse ethnic backgrounds. My personal goal is to promote diversity, equity and inclusion at UCSF.
  Award  
  Confired By    
  Date    
  • Distinguished Pharmaceutical Scientist Award
  • American Association of Pharmaceutical Scientists
  • 2021
  • B.B. Brodie Award
  • American Society of Pharmacology and Experimental Therapeutics
  • 2020
  • Volwiler Research Achievement Award
  • American Association of Colleges of Pharmacy
  • 2018
  • Scheele Award
  • Swedish Academy of Pharmaceutical Scientists
  • 2011
  • Therapeutic Frontiers Lecture Award
  • Therapeutic Frontiers Lecture Award
  • 2010
  • Rawls-Palmer Progress in Medicine Award
  • American Society for Clinical Pharmacology and Therapeutics
  • 2009
  • Outstanding Mentor Award
  • Postdoctoral Scholars Association, University of California, San Francisco
  • 2009
  • Invitation Fellowship Program for Research in Japan
  • Japan Society for the Promotion of Science
  • 2008
  • International Woman Scientist Award
  • Academy of Pharmaceutical Sciences and Technology, Japan
  • 2007
  • Research Achievement Award
  • Pharmaceutical Sciences World Congress
  • 2007
  • Distinguished Scientist Award in Drug Metabolism
  • American Association of Pharmaceutical Scientists
  • 2006
  • Elected Member
  • National Academy of Medicine
  • 2006
  • Paul Dawson Biotechnology Award
  • American Association of Colleges of Pharmacy
  • 2005
  • Distinguished Gerhard Levy Lectureship
  • State University of New York at Buffalo
  • 2002
  • Distinguished Bill Abram's Lectureship
  • U.S. Food and Drug Administration
  • 2002
  • Honored Celebrating Women Faculty
  • University of California, San Francisco
  • 2002
  • Guttman Lecturer
  • University of Kentucky
  • 2000
  • Scientist of the Year
  • International Pharmaceutical Federation (FIP)
  • 1999
  • Recognition Award for Distinguished Achievement of a Filipino at UCSF
  • University of California, San Francisco
  • 1999
  • Chancellor's Award for the Advancement of Women
  • University of California, San Francisco
  • 1997
  • Martin Luther King, Jr. Award for the Advancement of Minorities
  • University of California, San Francisco
  • 1994
  • Fogarty International Fellowship
  • National Institutes of Health
  • 1992
  • Leon Goldberg Young Investigator Award
  • American Society for Clinical Pharmacology and Therapeutics
  • 1990
  • Data provided by UCSF Profiles, powered by CTSI
    ORCID iD: 0000-0001-8041-5430 Additional info
    • Characterizing the physiological and pharmacological roles of SLC22A24
      Sponsor:
      Sponsor ID:
      Funding Period:
      Apr 2021
      -
      Mar 2025
      Principal Investigator
    • Discovery of Pharmacogenomic Biomarkers for OATP1B1 and OATP1B3
      Sponsor:
      Sponsor ID:
      Funding Period:
      Sep 2015
      -
      Jul 2024
      Principal Investigator
    • UCSF-Stanford Center of Excellence in Regulatory Science and Innovation
      Sponsor:
      Sponsor ID:
      Funding Period:
      Sep 2016
      -
      Aug 2023
      Principal Investigator
    • PGRN Administrative Coordination Hub, ACH (PGRN)
      Sponsor:
      Sponsor ID:
      Funding Period:
      Jul 2015
      -
      Jun 2020
      Principal Investigator
    • Role of ABCG2 in the disposition and anti-hyperuricemic effects of allopurinol
      Sponsor:
      Sponsor ID:
      Funding Period:
      Sep 2014
      -
      Jul 2018
      Principal Investigator
    • Center for Structure of Membrane Proteins
      Sponsor:
      Sponsor ID:
      Funding Period:
      Sep 2010
      -
      Jun 2016
      Co-Investigator
    • Pharmacogenomics of Membrane Transporters
      Sponsor:
      Sponsor ID:
      Funding Period:
      Apr 2000
      -
      Jun 2015
      Principal Investigator
    • A Comprehensive Platform for Transporter Mediated Drug-Drug Interaction Studies
      Sponsor:
      Sponsor ID:
      Funding Period:
      Feb 2009
      -
      Sep 2013
      Principal Investigator
    • Resource for Biocomputing, Visualization, and Informatics
      Sponsor:
      Sponsor ID:
      Funding Period:
      Jun 1976
      -
      Sep 2012
      Co-Investigator
    • Cellular Mechanisms of Drug Elimination
      Sponsor:
      Sponsor ID:
      Funding Period:
      Apr 1986
      -
      May 2012
      Principal Investigator
    • Pharmacogenetics of Membrane Transporters
      Sponsor:
      Sponsor ID:
      Funding Period:
      Apr 2000
      -
      Jul 2010
      Principal Investigator
    • General Clinical Research Center
      Sponsor:
      Sponsor ID:
      Funding Period:
      Dec 1974
      -
      Mar 2009
      Co-Investigator
    • CELLULAR MECHANISMS OF DRUG TRANSPORT IN CHOROID PLEXUS
      Sponsor:
      Sponsor ID:
      Funding Period:
      Jan 1991
      -
      Dec 2003
      Principal Investigator
    • MOLECULAR BASIS OF DRUG TRANSPORT IN THE INTESTINE
      Sponsor:
      Sponsor ID:
      Funding Period:
      Aug 1997
      -
      Jul 2001
      Principal Investigator
    • PHARMACOKINETICS/PHARMACODYNAMICS
      Sponsor:
      Sponsor ID:
      Funding Period:
      Aug 1979
      -
      Jul 1998
      Co-Investigator
    • STEREOSELECTIVE PHARMACOKINETICS OF DRUGS IN THE KIDNEY
      Sponsor:
      Sponsor ID:
      Funding Period:
      Mar 1983
      -
      Jun 1989
      Principal Investigator
    • MOLECULAR MECHANISMS OF DRUG TRANSPORT
      Sponsor:
      Sponsor ID:
      Funding Period:
      Jan 1992
      -
      Jan 0001
      Principal Investigator
    MOST RECENT PUBLICATIONS FROM A TOTAL OF 336
    Data provided by UCSF Profiles, powered by CTSI
    1. Martinez MN, Sinko B, Wu F, Flanagan T, Borbás E, Tsakalozou E, Giacomini KM. A Critical Overview of the Biological Effects of Excipients (Part I): Impact on Gastrointestinal Absorption. AAPS J. 2022 05 02; 24(3):60. View in PubMed
    2. Giacomini KM, Yee SW, Koleske ML, Zou L, Matsson P, Chen EC, Kroetz DL, Miller MA, Gozalpour E, Chu X. New and Emerging Research on Solute Carrier and ATP Binding Cassette Transporters in Drug Discovery and Development: Outlook From the International Transporter Consortium. Clin Pharmacol Ther. 2022 09; 112(3):540-561. View in PubMed
    3. Dawed AY, Yee SW, Zhou K, van Leeuwen N, Zhang Y, Siddiqui MK, Etheridge A, Innocenti F, Xu F, Li JH, Beulens JW, van der Heijden AA, Slieker RC, Chang YC, Mercader JM, Kaur V, Witte JS, Lee MTM, Kamatani Y, Momozawa Y, Kubo M, Palmer CNA, Florez JC, Hedderson MM, 't Hart LM, Giacomini KM, Pearson ER, for MetGen Plus, for the DIRECT Consortium. Response to Comment on Dawed et al. Genome-Wide Meta-analysis Identifies Genetic Variants Associated With Glycemic Response to Sulfonylureas. Diabetes Care 2021;44:2673-2682. Diabetes Care. 2022 04 01; 45(4):e82-e83. View in PubMed
    4. Giacomini KM, van der Graaf PH. The Pandemic as a Catalyst for Disruptive Innovation in Clinical Pharmacology. Clin Pharmacol Ther. 2022 03; 111(3):529-532. View in PubMed
    5. Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 05; 111(5):1007-1021. View in PubMed
    6. View All Publications

     

    Site Directory
      X